DNA repair, cell cycle pathways, BRCA mutation
The Women's Malignancies Branch (WMB), Center for Cancer Research (CCR), National Cancer Institute (NCI) of the National Institutes of Health (NIH) is seeking outstanding postdoctoral candidates interested in studying DNA repair and cell cycle pathways in the context of ovarian cancer and drug resistance. Our broad goal is to explore the molecular and cellular mechanisms of drug resistance (e.g., PARP inhibitors or cell cycle checkpoint inhibitors) in the context of ovarian cancer. With ongoing and new preclinical projects, we have translational aims of developing novel molecular biomarkers and therapeutic targets based on an understanding of the clinical resistance mechanisms to targeted agents active in recurrent ovarian cancer.
This is a great opportunity for candidates who are interested in cancer biology and want to enhance their career potential by working in our clinical/translational research program with the outstanding support of other established laboratories and core facilities in the NCI. This laboratory effort will be in close collaboration with other faculty in our branch.
Qualified candidates should have a Ph.D. in a biological science area or the equivalent background (M.D., M.B.B.S., etc.). A background and working knowledge in molecular and cellular biology is required. Familiarity with basic techniques including DNA/RNA isolation, cell culture techniques, Western-blot, quantitative PCR, immunohistochemistry, ChIP, retroviral or lentiviral transfections, FACS sorting, and working with mice are a must. Knowledge and/or experience in bioinformatics, biostatistics, mutation detection, microarray analysis, RNA-seq and other sequencing methodology, and microRNA is preferred. Previous research experience in cancer biology is advantageous, but not required.
Applicants should send their CV, cover letter and letters of recommendation directly to Dr. Jung-Min Lee at firstname.lastname@example.org.
HHS, NIH, and NCI are Equal Opportunity Employers